A more refined approach
C4X's (LON:C4XD) interims revealed a refinement of its hybrid business model, whereby it will stop offering access to its drug discovery technology on a fee-for-service basis, instead seeking to strike more strategic and collaborative agreements with pharma/biotech partners. The recent £1.67m acquisition of Adorial, with an innovative technology to help identify novel drug targets, could significantly enhance and accelerate C4X’s drug discovery capabilities. With £5m in cash as of 31 January 2016, and operating costs on the rise to support pipeline and technology development, we anticipate a fresh financing in H216.
Therapeutic programmes progress
C4X has made progress across a number of therapeutic areas with six pre-clinical projects underway. A number of new drug candidates have been identified across addiction, inflammation and diabetes, with the lead programme, Orexin-1 (for the treatment of addictive disorders) continuing to make good progress with a preclinical candidate and a second differentiated follow-up molecule identified. We anticipate clinical studies to start in mid-2017.
To read the entire report Please click on the pdf File Below